Research: AMADOR-LICONA and COLLEAGUES,

Listed in Issue 275

Abstract

AMADOR-LICONA and COLLEAGUES, 1. Department of Education and Research, UMAE HE No.1, Bajio, Instituto Mexicano del Seguro Social, Mexico City, Mexico; 2. Laboratory of oxidative stress & Pathology, Centro de Investigacion Biomedica de Occidente, Instituto Mexicano del Seguro Social, Guadalajara, Mexico; 3. Department of Chemistry, University of Guadalajara, Guadalajara, Mexico; 4. University DeLa Salle Bajio, Leon, Mexico; 5. Department of Research, University of Guanajuato, Leon, Mexico; 6. Institute of Research on Inflammation, Guadalajara, Jalisco, Mexico conducted a randomized clinical trial to assess the effect of omega 3 fatty acids on different markers of oxidative stress in HIV-seropositive patients.

Background

HIV-seropositive patients show high incidence of coronary heart disease and oxidative stress has been described as relevant key in atherosclerosis development.

Methodology

The aim of this study was to assess the effect of omega 3 fatty acids on different markers of oxidative stress in HIV-seropositive patients. We performed a randomized parallel controlled clinical trial in The Instituto Mexicano del Seguro Social, a public health hospital. 70 HIV-seropositive patients aged 20 to 55 on clinical score A1, A2, B1 or B2 receiving highly active antiretroviral therapy (HAART) were studied. They were randomly assigned to receive omega 3 fatty acids 2.4 g (Zonelabs, Marblehead MA) or placebo for 6 months. At baseline and at the end of the study, anthropometric measurements, lipid profile, glucose and stress oxidative levels [nitric oxide catabolites, lipoperoxides (malondialdehyde plus 4-hydroxialkenals), and glutathione] were evaluated.

Results

Principal HAART therapy was EFV/TDF/FTC (55%) and AZT/3TC/EFV (15%) without difference between groups. Treatment with omega 3 fatty acids as compared with placebo decreased triglycerides (-0.32 vs. 0.54 mmol/L; p = 0.04), but oxidative stress markers were not different between groups. Trial Registration: ClinicalTrials.gov NCT02041520.

Conclusion

References

Amador-Licona N1, Díaz-Murillo TA1, Gabriel-Ortiz G2, Pacheco-Moises FP3, Pereyra-Nobara TA1, Guízar-Mendoza JM4, Barbosa-Sabanero G5, Orozco-Aviña G6, Moreno-Martínez SC1, Luna-Montalbán R1, Vázquez-Valls E2. Omega 3 Fatty Acids Supplementation and Oxidative Stress in HIV-Seropositive Patients. A Clinical Trial. PLoS One. 11(3):e0151637. Mar 25 2016. doi: 10.1371/journal.pone.0151637. eCollection 2016.

ICAN Skyscraper

Scientific and Medical Network 2

Royal Rajasthan Cycle 2021

Amazon Wilderness Trek 2022

Cycle Kilimanjaro to the Coast 2022

top of the page